Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications
Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications
复制标题
DOI：
10.3390/cryst13071067
复制
发表时间：
2023-07
期刊：
影响因子：
2.7
通讯作者：
Melissa Venedicto;Jake Carrier;H. Na;Chen-Yu Chang;D. Radu;Cheng-Yu Lai
中科院分区：
文献类型：
--
作者：
Melissa Venedicto;Jake Carrier;H. Na;Chen-Yu Chang;D. Radu;Cheng-Yu Lai
介孔二氧化硅纳米颗粒（MSNs）是用于生物医学应用的药物和基因递送研究的高度多孔载体，这是由于它们的高表面积、窄粒度分布和低毒性。将二硫键（SS）插入到MSNs（MSN-SS）的壁中提供了药物释放的双重途径，这是由于孔递送和细胞吞噬后的多孔结构塌陷。本研究通过各种结构和生物学表征方法探讨了嵌入二硫键到MSN中的效果。采用拉曼光谱检测SS键，SEM和TEM进行形态分析，BET分析确定获得最大表面积所需的SS量。MSN-SS进一步装载有抗癌药物多柔比星，以评估在各种pH条件下的药物释放行为。MSN-SS系统表现出有效的pH响应性药物释放，在酸性条件下释放超过65%的多柔比星，在中性条件下释放超过15%。使用二硫苏糖醇裂解SS键，在酸性条件下释放增加到94%，在中性条件下释放增加到46%。使用癌细胞进行生物相容性研究以验证纳米颗粒的吞噬。这些结果表明，MSN-SS是一种可行的纳米载体控制释放药物。
Mesoporous silica nanoparticles (MSNs) are highly porous carriers used in drug and gene delivery research for biomedical applications due to their high surface area, narrow particle size distribution, and low toxicity. Incorporating disulfide (SS) bonds into the walls of MSNs (MSN-SSs) offers a dual pathway for drug release due to the pore delivery and collapsing porous structure after cellular engulfment. This study explores the effect of embedding disulfide bonds into MSNs through various structural and biological characterization methods. Raman spectroscopy is employed to detect the SS bonds, SEM and TEM for morphology analyses, and a BET analysis to determine the required amount of SSs for achieving the largest surface area. The MSN-SSs are further loaded with doxorubicin, an anticancer drug, to assess drug release behavior under various pH conditions. The MSN-SS system demonstrated an efficient pH-responsive drug release, with over 65% of doxorubicin released under acidic conditions and over 15% released under neutral conditions. Cleaving the SS bonds using dithiothreitol increased the release to 94% in acidic conditions and 46% in neutral conditions. Biocompatibility studies were conducted using cancer cells to validate the engulfment of the nanoparticle. These results demonstrate that MSN-SS is a feasible nanocarrier for controlled-release drug delivery.